ArticleCureus2024
A Case of Extensive Lichen Planus Treated With Deucravacitinib.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and Safety of JAK Inhibitors in Lichen Planus: A Systematic Review of the Available Clinical Evidence.Mediators of inflammation · 2026Pooled it
- Deucravacitinib for refractory lichen planus with post-inflammatory hyperpigmentation in skin of color.JAAD case reports · 2026Article
- Successful treatment of generalized lichen planus with deucravacitinib monotherapy.JAAD case reports · 2026Article
- Deucravacitinib in dermatology: current indication and existing off-label data.Drugs in context · 2026Review
- [Drug-induced lichen planus responsive to upadacitinib treatment].Dermatologie (Heidelberg, Germany) · 2025Article
- Use of JAK Inhibitors in Lichen Planus: An Update.Medicina (Kaunas, Lithuania) · 2025Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lichen planus (LP) is a persistent inflammatory condition that affects the skin and mucous membranes, often significantly impacting quality of life. Recent research has highlighted the potential of Janus kinase (JAK) inhibitors as an effective treatment for LP. We report a case of a 52-year-old woman with a history of hypertension, obesity, and hypothyroidism who presented with a widespread, itchy, and scaly rash that was present for one month and affected 80% of her body surface area (BSA). A biopsy from the right lower extremity confirmed LP. After two months of treatment with deucravacitinib, the patient demonstrated significant improvement, with BSA involvement reduced to 20% and erythema notably diminished. To our knowledge, this is the first documented case of extensive cutaneous LP successfully managed with deucravacitinib. Unlike other JAK inhibitors, deucravacitinib selectively targets tyrosine kinase 2 (Tyk2), offering focused modulation of the immune response while minimizing broader adverse effects. This specificity provides deucravacitinib with a more favorable safety profile, making it a potentially ideal option for the long-term management of chronic dermatologic conditions like LP, which often require extended treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.